Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ehealth (EHTH – Research Report), Akero Therapeutics (AKRO – Research Report) and Omnicell (OMCL – Research Report).
Ehealth (EHTH)
RBC Capital analyst Ben Hendrix maintained a Hold rating on Ehealth yesterday and set a price target of $13.00. The company’s shares closed last Friday at $8.89.
According to TipRanks.com, Hendrix is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Ehealth with a $10.67 average price target, a 21.9% upside from current levels. In a report issued on August 9, Deutsche Bank also maintained a Hold rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
Akero Therapeutics (AKRO)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Akero Therapeutics today and set a price target of $64.00. The company’s shares closed last Friday at $47.55.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Akero Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $65.25, a 41.5% upside from current levels. In a report issued on August 11, LifeSci Capital also maintained a Buy rating on the stock with a $68.00 price target.
Omnicell (OMCL)
Wells Fargo analyst Stan Berenshteyn maintained a Sell rating on Omnicell today and set a price target of $56.00. The company’s shares closed last Friday at $66.45.
According to TipRanks.com, Berenshteyn is a 1-star analyst with an average return of
Omnicell has an analyst consensus of Moderate Buy, with a price target consensus of $72.63.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EHTH:
